1. Home
  2. SOWG vs MDXH Comparison

SOWG vs MDXH Comparison

Compare SOWG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

N/A

Current Price

$2.47

Market Cap

69.9M

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.63

Market Cap

68.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
MDXH
Founded
2010
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
69.9M
68.7M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
SOWG
MDXH
Price
$2.47
$0.63
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
16.2K
238.6K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.40
52 Week High
$4.45
$5.33

Technical Indicators

Market Signals
Indicator
SOWG
MDXH
Relative Strength Index (RSI) 41.81 45.51
Support Level $2.45 $0.51
Resistance Level $3.65 $0.75
Average True Range (ATR) 0.39 0.04
MACD -0.05 -0.02
Stochastic Oscillator 11.60 7.49

Price Performance

Historical Comparison
SOWG
MDXH

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: